ClinicalTrials.gg

Program

Biological Products

Also written as “Biological”, “AAV2-GDNF gene therapy” and “Biological/Vaccine: BNT162b2 10mcg”.

Its studies are mostly in Parkinson Disease · COVID-19 · Diabetes Mellitus, Type 1 · Carcinoma, Renal Cell · Metabolic Diseases, led by 11 companies.

Furthest: phase 3, since Dec 6, 201712 company-led studies, 5 open or runningNext primary completion: Aug 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immune Cell22 open or runningphase 1since Dec 6, 2017Dec 6, 2017none ahead
Anchiano Therapeutics Israel10 open or runningphase 2since Aug 8, 2011Aug 8, 2011none ahead
Bayer11 open or runningphase 2since Feb 14, 2024Feb 14, 2024Aug 31, 2028phase 2 · NCT06285643
BioNTech10 open or runningphase 3since Mar 19, 2021Mar 19, 2021none ahead
diavacs-inc10 open or runningphase 2since Sep 18, 2013Sep 18, 2013none ahead
GAIA BioMedicine10 open or runningphase 2since Nov 19, 2021Nov 19, 2021none ahead
Lisata Therapeutics10 open or runningphase 1since Apr 10, 2001Apr 10, 2001none ahead
Longeveron10 open or runningphase 2since Oct 23, 2015Oct 23, 2015none ahead
Sanofi11 open or runningphase 1since Nov 24, 2025Nov 24, 2025none ahead
Sinopharm10 open or runningphase 2since Jun 11, 2020Jun 11, 2020none ahead
Vertex Pharmaceuticals11 open or runningphase 3since Feb 13, 2025Feb 13, 2025none ahead

Also a collaborator on its studies: Pfizer, chengdu-institute-of-biological-products-co-ltd and simoon-record-pharma-information-consulting-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2001First study: phase 1 study in Kidney NeoplasmsNew to Lisata TherapeuticsLisata Therapeutics · NCT00014131 · 9 enrolled · United States
  2. Aug 8, 2011Anchiano Therapeutics Israel's first study: phase 2 study in AdenocarcinomaNew to Anchiano Therapeutics IsraelAnchiano Therapeutics Israel · NCT01413087 · 12 enrolled · United States, Israel
  3. Sep 18, 2013diavacs-inc's first study: phase 2 study in Treatment of Type I Diabetes Mellitus.New to diavacs-incdiavacs-inc · NCT01947569 · 90 enrolled · United States
  4. Oct 23, 2015Longeveron's first study: phase 2 study in Metabolic DiseasesNew to LongeveronLongeveron · NCT02587572
  5. Dec 6, 2017Immune Cell's first studies: 2 phase 1 studiesNew to Immune CellImmune Cell · NCT03383965, NCT03383952
  6. Jun 11, 2020Sinopharm's first study: phase 2 study in Papillomavirus InfectionsNew to SinopharmSinopharm · NCT04436133 · 480 enrolled · China
  7. Mar 19, 2021BioNTech's first study: phase 3 study in COVID-19New to BioNTechBioNTech · NCT04816643 · 11,837 enrolled · United States, Brazil, Finland and more
  8. Nov 19, 2021GAIA BioMedicine's first study: phase 2 study in Cell TherapyNew to GAIA BioMedicineGAIA BioMedicine · NCT05207371 · 22 enrolled · Japan
  9. Feb 14, 2024Bayer's first study: phase 2 study in Parkinson DiseaseNew to BayerBayer · NCT06285643 · 59 enrolled · United States, Germany, Poland and more
  10. Feb 13, 2025Vertex Pharmaceuticals's first study: phase 3 study in Diabetes Mellitus, Type 1New to Vertex PharmaceuticalsVertex Pharmaceuticals · NCT06832410 · 10 planned · United States, Canada, Saudi Arabia
  11. Nov 24, 2025Sanofi's first study: phase 1 study in Lower Respiratory Tract DiseaseNew to SanofiSanofi · NCT07295028 · 240 enrolled · Australia

Ahead

  1. Aug 31, 2028Primary completion: phase 2 study in Parkinson DiseaseBayer · NCT06285643

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07295028Lower Respiratory Tract Disease · Australia1Active, not recruitingSanofiApr 21, 2026240
NCT06832410Diabetes Mellitus, Type 1 · United States, Canada, Saudi Arabia3RecruitingVertex PharmaceuticalsSep 17, 202610
NCT06285643Parkinson Disease · United States, Germany, Poland and more2Active, not recruitingBayerAug 31, 202859
NCT05207371Cell Therapy · Japan2TerminatedGAIA BioMedicineSep 1, 202422
NCT04816643COVID-19 · United States, Brazil, Finland and more3CompletedBioNTechOct 4, 202311,837
NCT04436133Papillomavirus Infections · China2CompletedSinopharmMar 1, 2022480
NCT03383965Hodgkin Disease · China1RecruitingImmune CellDec 31, 202020
NCT03383952Leukemia, B-Cell · China1RecruitingImmune CellDec 31, 202020
NCT02587572Metabolic Diseases2WithdrawnLongeveronDec 20230
NCT01947569Treatment of Type I Diabetes Mellitus. · United States2UNKNOWNdiavacs-incNov 201490
NCT01413087Adenocarcinoma · United States, Israel2TerminatedAnchiano Therapeutics IsraelJan 201312
NCT00014131Kidney Neoplasms · United States1TerminatedLisata TherapeuticsDec 20099

How it is read

Names in the registry

  • “Biological”, 2 entries
  • “AAV2-GDNF gene therapy”, 1 entry
  • “Biological/Vaccine: BNT162b2 10mcg”, 1 entry
  • “Biological/Vaccine: BNT162b2 3mcg”, 1 entry
  • “Biological/Vaccine: monovalent (hMPV) unlicensed comparator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.